{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:08:59Z","timestamp":1789711739564,"version":"4.0.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To systematically evaluate how type 2 (T2) inflammation-related biomarkers are incorporated into multivariable models that predict future acute exacerbations in adults with asthma, and to appraise model performance, validation, calibration, risk of bias, and clinical applicability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, Web of Science, the Cochrane Library, and Scopus were searched from inception to May 2026, followed by a supplementary PubMed update through 31 July 2026. Eligible reports contained at least one adult cohort used to develop, validate, or update a longitudinal multivariable model for a future exacerbation outcome, incorporated at least one T2-related biomarker, and reported model performance or validation. Mixed-age cohorts were not counted as independent adult evidence; only performance evaluated in an adult cohort contributed to the main synthesis. Association-only studies, current-attack classification models, post-exacerbation disposition models, and post-index relapse models outside the prespecified baseline-risk setting were excluded. Data extraction followed CHARMS, and risk of bias and applicability were assessed using PROBAST.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eight reports published from 2021 to 2026 were included. Eligible adult cohorts ranged from 540 to 1,331,934 participants; one report also included a mixed-age randomized-trial comparator (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009345). Modeling approaches included logistic and elastic-net regression, gradient-boosting and deep-learning algorithms, Bayesian networks, and a mixed-effects count model. Eosinophil-related variables appeared in all eight reports but were not retained in every final model; FeNO was included in two multinational severe-asthma registry models, and serum IgE appeared as a network node in one cross-source analysis and was retained in an independently replicated metabolomics model. The metabolomics model reported AUCs of 0.901 and 0.893 in discovery and replication cohorts, whereas an RCT-derived Bayesian network achieved an AUC of 0.68 when validated in the adult ISAR cohort. Six reports were rated at high overall risk of bias, mainly because of analysis-domain limitations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>T2-related biomarkers may add complementary information to adult asthma exacerbation-risk models, but the available evidence does not yet establish BEC, FeNO, or IgE as independently sufficient predictors or support routine implementation of an existing model. Future studies should quantify incremental biomarker value beyond established clinical predictors and prioritize adequate sample size, external validation, calibration, clinical utility, transparent handling of missing biomarker data, and reproducible model presentation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , PROSPERO CRD420261415469.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1900214","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:38:50Z","timestamp":1789709930000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Application of type 2 inflammation-related biomarkers in risk prediction models for acute exacerbations in adult asthma: a systematic review"],"prefix":"10.3389","volume":"13","author":[{"given":"Minghao","family":"Li","sequence":"first","affiliation":[{"name":"Lung Disease Diagnosis and Treatment Center, National Medical Center, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Yan","sequence":"additional","affiliation":[{"name":"Lung Disease Diagnosis and Treatment Center, National Medical Center, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghang","family":"Wang","sequence":"additional","affiliation":[{"name":"Lung Disease Diagnosis and Treatment Center, National Medical Center, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]},{"name":"Collaborative Innovation Center for Chinese Medicine Prevention and Treatment of Respiratory Diseases Co-constructed by Province and Ministry","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","volume-title":"Global Strategy for Asthma Management and Prevention, 2026","year":"2026"},{"key":"B2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1164\/rccm.200801-060ST","article-title":"An official American thoracic society\/European respiratory society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice","volume":"180","author":"Reddel","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/S0140-6736(17)33311-1","article-title":"Asthma","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2003393","DOI":"10.1183\/13993003.03393-2020","article-title":"Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation","volume":"58","author":"Busse","year":"2021","journal-title":"Eur Respir J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nri3786","article-title":"Type 2 inflammation in asthma-present in most, absent in many","volume":"15","author":"Fahy","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.resinv.2025.01.003","article-title":"Guidance for type 2 inflammatory biomarkers","volume":"63","author":"Matsunaga","year":"2025","journal-title":"Respir Investig"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-014-0241-z","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"13","author":"Collins","year":"2015","journal-title":"BMC Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2147\/JAA.S445450","article-title":"Primary care asthma attack prediction models for adults: a systematic review of reported methodologies and outcomes","volume":"17","author":"Ma","year":"2024","journal-title":"J Asthma Allergy"},{"key":"B9","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2147\/JAA.S509260","article-title":"An updated systematic review on asthma exacerbation risk prediction models between 2017 and 2023: risk of bias and applicability","volume":"18","author":"Liu","year":"2025","journal-title":"J Asthma Allergy"},{"key":"B10","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13643-020-01542-z","article-title":"PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews","volume":"10","author":"Rethlefsen","year":"2021","journal-title":"Syst Rev"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e1001744","DOI":"10.1371\/journal.pmed.1001744","article-title":"Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist","volume":"11","author":"Moons","year":"2014","journal-title":"PLoS Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.7326\/M18-1376","article-title":"PROBAST: a tool to assess the risk of bias and applicability of prediction model studies","volume":"170","author":"Wolff","year":"2019","journal-title":"Ann Intern Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"i6460","DOI":"10.1136\/bmj.i6460","article-title":"A guide to systematic review and meta-analysis of prediction model performance","volume":"356","author":"Debray","year":"2017","journal-title":"Br Med J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.chest.2020.12.051","article-title":"Novel machine learning can predict acute asthma exacerbation","volume":"159","author":"Zein","year":"2021","journal-title":"Chest"},{"key":"B16","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s12325-024-03053-y","article-title":"Predicting asthma exacerbations using machine learning models","volume":"42","author":"Turcatel","year":"2025","journal-title":"Adv Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41533-025-00428-8","article-title":"Development and validation of a machine learning risk prediction model for asthma attacks in adults in primary care","volume":"35","author":"Tibble","year":"2025","journal-title":"NPJ Prim Care Respir Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"01218","DOI":"10.1183\/23120541.01218-2024","article-title":"Predictors of asthma exacerbation between high and low blood eosinophil counts","volume":"11","author":"Pham","year":"2025","journal-title":"ERJ Open Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.chest.2026.01.009","article-title":"Interactive pathways of key prognostic factors in severe asthma: a Bayesian network comparison of clinical trials and real-world data","volume":"169","author":"Yadav","year":"2026","journal-title":"Chest"},{"key":"B20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41467-025-67436-7","article-title":"The ratio of circulatory levels of sphingolipids to steroids predicts asthma exacerbations","volume":"17","author":"Chen","year":"2026","journal-title":"Nat Commun"},{"key":"B21","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.chest.2025.04.046","article-title":"Prediction pathway for severe asthma exacerbations: a Bayesian network analysis","volume":"168","author":"Yadav","year":"2025","journal-title":"Chest"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.jaip.2026.03.017","article-title":"Development and validation of the risk of exacerbation in severe asthma (RESA) model","volume":"14","author":"Chen","year":"2026","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B23","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.anai.2023.04.025","article-title":"Electronic medical record-based machine learning predicts the relapse of asthma exacerbation","volume":"131","author":"Lee","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1016\/j.jaip.2018.02.004","article-title":"Exacerbations in adults with asthma: a systematic review and external validation of prediction models","volume":"6","author":"Loymans","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B25","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","article-title":"Assessing the performance of prediction models: a framework for traditional and novel measures","volume":"21","author":"Steyerberg","year":"2010","journal-title":"Epidemiology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"100547","DOI":"10.1016\/j.waojou.2021.100547","article-title":"Variability of type 2 inflammatory markers guiding biologic therapy of severe asthma: a 5-year retrospective study from a single tertiary hospital","volume":"14","author":"Li","year":"2021","journal-title":"World Allergy Organ J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S2213-2600(20)30053-9","article-title":"Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial","volume":"8","author":"Pavord","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/j.jaip.2020.03.038","article-title":"Prospective, single-arm, longitudinal study of biomarkers in real-world patients with severe asthma","volume":"8","author":"Buhl","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e074819","DOI":"10.1136\/bmj-2023-074819","article-title":"Evaluation of clinical prediction models (part 1): from development to external validation","volume":"384","author":"Collins","year":"2024","journal-title":"Br Med J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12916-019-1466-7","article-title":"Calibration: the achilles heel of predictive analytics","volume":"17","author":"Van Calster","year":"2019","journal-title":"BMC Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12931-016-0360-5","article-title":"Longitudinal stability of asthma characteristics and biomarkers from the airways disease endotyping for personalized therapeutics (ADEPT) study","volume":"17","author":"Silkoff","year":"2016","journal-title":"Respir Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/S2213-2600(21)00124-7","article-title":"Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis","volume":"9","author":"Busse","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13601-019-0282-7","article-title":"Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations","volume":"9","author":"Price","year":"2019","journal-title":"Clin Transl Allergy"},{"key":"B34","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications","volume":"184","author":"Dweik","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S2213-2600(20)30397-0","article-title":"Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel-group, randomised controlled trial","volume":"9","author":"Heaney","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1002\/sim.7992","article-title":"Minimum sample size for developing a multivariable prediction model: part II-binary and time-to-event outcomes","volume":"38","author":"Riley","year":"2019","journal-title":"Stat Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"4230","DOI":"10.1002\/sim.9025","article-title":"Minimum sample size for external validation of a clinical prediction model with a binary outcome","volume":"40","author":"Riley","year":"2021","journal-title":"Stat Med"},{"key":"B38","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0272989X06295361","article-title":"Decision curve analysis: a novel method for evaluating prediction models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med Decis Making"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1136\/bmj.332.7549.1080","article-title":"The cost of dichotomising continuous variables","volume":"332","author":"Altman","year":"2006","journal-title":"Br Med J"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD\u2009+\u2009AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"Br Med J"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1900214\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:38:51Z","timestamp":1789709931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1900214\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":40,"alternative-id":["10.3389\/fmed.2026.1900214"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1900214","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1900214"}}